水蛭颗粒联合优甲乐治疗桥本甲减的疗效观察

《水蛭颗粒联合优甲乐治疗桥本甲减的疗效观察》由会员上传分享，免费在线阅读，更多相关内容在学术论文-天天文库。

1、提要目的：观察水蛭颗粒联合优甲乐治疗桥本甲状腺炎合并甲状腺功能减退的临床疗效。方法：将60例桥本甲状腺炎合并甲状腺功能减退患者随机分成治疗组（30例）及对照组（30例），其中治疗组予以水蛭颗粒和左旋甲状腺素片（优甲乐），对照组仅予以优甲乐，疗程3个月，观察其临床症状、甲状腺肿、甲功、自身抗体、血脂的变化，进行统计学分析。结果：本研究显示，治疗组和对照组都具有一定的临床疗效，且治疗组优于对照组。治疗组和对照组患者的症状和体征均有所改善，治疗组患者改善更明显，特别是甲状腺肿大程度；对甲状腺功能改善情况，治疗组明显优于对照组；两组甲状腺球蛋白抗体和甲状腺过氧

2、化物酶抗体指标均降低，治疗组前后相比具有显著差异；两组均未出现明显不良反应。结论：运用水蛭颗粒联合优甲乐治疗桥本甲状腺炎合并甲状腺功能减退较单纯使用优甲乐治疗具有更好的疗效。关键词桥本甲状腺炎；甲状腺功能减退；水蛭颗粒；临床观察ClinicalStudyofTheLeechparticlesJointEuthyroxonTreatingtheHashimoto'sthyroiditisassociatedwithHypothyroidismSpecialty:TCM-EndocrinologyAuthor:DengZhongqiTutor:Prof.Y

3、angWenjunAbstractObjective:ToobservetheclinicalefficacyofthetheleechparticlejointEuthyroxPatientswithHashimotothyroiditisassociatedwithhypothyroidism.Methods:60casesofHashimoto'sthyroiditisassociatedwiththyroiddysfunctionwererandomlydividedintotreatmentgroup(30cases)andcontrolgr

4、oup(30cases).ThetreatmentgroupItheleechparticlesandlevothyroxinesodium(Euthyrox),thecontrolgroup,onlytobeEuthyroxcourseof3months,toobservetheclinicalsymptoms,goiter,thyroidfunction,autoantibodies,lipidchanges,forstatisticalanalysis.Results:Thisstudyshowedthatthetreatmentgroupand

5、controlgroupwiththeclinicalefficacyofthetreatmentgroupthanthecontrolgroup;Treatmentgroupandcontrolgroupofpatientswithsymptomsandsignswereimproved,thetreatmentgroupimprovedmoresignificantly,inparticularthedegreeofgoiter;improvementofthyroidfunction,thetreatmentgroupthanthecontrol

6、group;Thetwogroupsofthyroglobulinantibodiesandthyroidperoxidaseantibodyindexwerelower,comparedtoasignificantdifferencebeforeandafterthetreatmentgroup;thetwogroupswerenotobviousadversereactions.Conclusion:TheuseofleechesparticlejointEuthyroxtreatmentwithHashimoto'sthyroiditisasso

7、ciatedwiththyroiddysfunctionthanasimpleEuthyroxtreatmentwithbetterefficacyKeywordsHashimoto'sthyroiditis;Hypothyroidism;Leechparticles;ClinicalStudy目录引言...............................................................................................................................

8、1临床研究..........................................